KEY WORDS Human papillomavirus, condgloma acuminatum, herpesvirus, human immunodeficiency virus, antivirals nterferons, naturally occuring glycoproteins with molecular weights of approximately 20,000 daltons, possess antiviral, antiproliferative, and immune-stimulating properties. They are classified into 3 antigenically distinct forms that are derived from different cell types. Alpha (or) interferons are derived from leukocytes, beta ([3) interferons from fibroblasts, and gamma (/) interferons from T lym-
phocytes. They have been approved for use in the treatment of condylomata acuminata, hepatitis B and C, and hairy-cell leukemia.
While naturally occurring ot interferons can be obtained from pooled leukocytes derived from whole blood and then stimulated to produce interferon [or-n3 Alferon (Purdue Frederick Company, Norwalk, CT); or-N1 WellferonTM (Pacific Pharmacy, San Francisco, CA)], they can also be produced through recombinant DNA technology [o-2a RoferonT= (Roche Laboratories, Nutley, NJ); ot-2b Intron A (Schering Corporation, Kenilworth, NJ)]. ot-2a and ot-2b differ by only amino acid in position -23. The natural interferons are really mixtures of 14 or more types, while the recombinant types are pure quantities of a single species of interferon.
MECHANISM OF ACTION
As indicated above, interferons are antiviral, antiproliferative, and immune-stimulating. The mechanism by which interferons block viral replication is by inducing more than 24 different cellular proteins that degrade viral RNA and interfere with viral protein synthesis. The antiproliferative activity of interferons has been utilized in slowing the growth of tumor cells. This cytostatic effect is achieved by a modulation of the levels of cellular 2',5'-oligoadenylate synthetase and of cell oncogenes such as c-myc, c-fos, and c-H-ras. The immune-stimulating properties contribute to the antiviral and antitumor activities by enhancing the expression of cell surface antigens, such as major histocompatibility complex antigens. Interferons contribute to the lysis of virus-infected and tumor cells by activating macrophages, natural killer cells, and cytotoxic T lymphocytes, as well as by cytokine induction.
PHARMACOKINETICS
The intramuscular administration of interferon produces peak plasma concentrations in 4-8 h. The elimination half-life is between 2 and 3 h. However, the physiologic half-life may extend far beyond this time. Little is known of the pharmacokinetics of the intralesional (intradermal) or topical administration. The activity is expressed in international units (I.U.) and vials containing 3, 5, 10, 25, and 50 million I.U. of recombinant interferon are commercially available. Once reconstituted with bacteriostatic water for injection, it is stable for month if refrigerated. Natural interferons (Alferon =) are available in 5 million I.U. vials which are stable for 6 months if kept refrigerated. An 0.1 ml quantity (usually million units) is injected intradermally with a number 30 needle into the base of each lesion 2-3 times weekly. An intradermal injection is performed in a similar manner to a purified protein derivative (PPD) injection. For intramuscular administration, usually 3 million I.U. is injected either "regionally" into the anterior thigh or "systemically" into the deltoid muscle.
SIDE EFFECTS
The most commonly reported side effects are flulike symptoms including myalgias, headache, fever, chills, nausea, and fatigue. Transient leukopenia, occasional thrombocytopenia, and clinically insignificant abnormalities of liver function tests all readily reverse with discontinuation of therapy. The development of antibodies to interferon in 1% of the recipients appears to have no clinical significance. The flu-like side effects are reduced by limiting the total dose to 3 or, at most, 5 million I.U.
per day and prophylactically administering acetaminophen immediately prior to therapy and again 6 h later when the chills and fever tend to occur. Another helpful technique is to administer the interferon late in the day, about 5 P.M. Since the chills and fever occur 6 h later, the patient can go to bed as usual and awaken in the morning free of side effects. With the subsequent administration of interferon, tachyphylaxis occurs with a lessening or disappearance of symptoms (except fatigue) by the second week. Interferon is contraindicated in pregnancy.
SPECTRUM OF ANTIVIRAL ACTIVITY
Interferons, although they have no direct antiviral activity in vitro, stimulate cells of the immune system to develop antiviral activity and to produce antiviral substances. Second, the intralesional injection twice or thrice weekly is a cumbersome, labor-intensive method of administration that is not adaptable to cervical or vaginal disease. Two alternative approaches circumvent these limitations: 1) topical application of interferon or an interferon inducer and 2) regional or systemic administration of interferon. After an early successful trial, topical interferon administration has not proved effective, although recent work using the topically applied imiquimod, a heterocyclic amine that induces interferon production in peripheral blood mononuclear cells, has demonstrated efficacy in a placebo-controlled, double-blind trial. The potential usefulness of a topical application in the treatment of cervical or vaginal disease and its lack of any systemic side effects make this compound an interesting one suitable for further clinical trials.
Regional (in the anterior thigh) or systemic (in the deltoid muscle) administration of interferon has been demonstrated to be effective in the treatment of hepatitis B and C (50% and 25% cure rates, respectively). However, it has not shown as much efficacy in the treatment of anogenital HPV infections. The cure rates of the systemic administration of interferons to treat condylomata acuminata have been disappointingly low. Adjuvant therapy with systemic interferon did not increase the efficacy of cryotherapy in eradicating condylomata acuminata either during or following treatment. 9'1 However, in 2 randomized trials, when interferon was administered regionally in the anterior thigh, it increased the efficacy of laser therapy in treating vulvar condylomata acuminata. 11'12 Why a discrepancy exists between laser therapy and cryotherapy when interferon is used as an adjuvant chemotherapy is unclear. It may have to do with the ability of the laser to eradicate the viral reservoir in the adjacent normal tissue. Alternatively, it may reflect the possible efficacy of the regional route (in the anterior thigh) compared with systemic administration (in the deltoid muscle) of interferon.
Systemic interferon therapy did not eliminate HPV DNA or reduce the amount of DNA present when genital warts were treated systemically with o interferon. 13'14 Similarily, ot interferon failed to eliminate HPV DNA from laryngeal papillomas that ERON were treated systemically with interferon, is Furthermore, neither 13 interferon nor ot interferon has shown greater efficacy when systemically administered as an adjuvant to cryotherapy. 16 Additionally, these interferons are less effective in the treatment of HIV-positive individuals, who have an especially high relapse rate. 17 These results suggest that systemically administered interferons work mainly as antiproliferative agents and have not yet fulfilled their antiviral and immune-stimulating potentials in the case of HPV infection. COST A 3 million I.U. vial, enough for a single treatment, costs $31.50 (wholesale price). However, this cost does not include the cost of administering the interferon. It has been calculated to cost approximately $1,500 for a course of therapy including the cost of administration. 6'9 Purchasing interferon in larger quantities such as 5 million ($52.50), 10 million ($105), or 18 million ($189) I.U. vials does not reduce the cost.
SUMMARY
Interferons are useful in treating recalcitrant or recurrent warts, but are certainly not first-line therapy. The intralesional administration is effective but limited to vulvar and penile disease. Regional administration in the anterior thigh may be useful as an adjuvant to superficial laser vulvectomy. Interferons have not been shown to have a systemic effect on anogenital warts when used either as primary therapy or as an adjuvant to cryotherapy. They have not been shown to reduce HPV DNA following systemic therapy. In early trials, a topical interferon inducer, imiquimod, appeared to be effective without systemic side effects. This form may also be useful in the treatment of vaginal and cervical disease.
